drugset
drugset / Trial / NCT06885645

First-In-Human Study in Participants With Advanced Solid Tumors

NCT06885645 ↗

Phase 1 Not yet recruiting 30 enrolled Chengdu Kanghong Biotech Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

A Phase 1 Study of KH815 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors

Timeline

Start
2025-04-30
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject KH815 Other / unclassified 0.5 mg/kg Intravenous
Subject KH815 Other / unclassified 1 mg/kg Intravenous
Subject KH815 Other / unclassified 2 mg/kg Intravenous
Subject KH815 Other / unclassified 3 mg/kg Intravenous
Subject KH815 Other / unclassified 4 mg/kg Intravenous

Indications

cancer